Dr Katherine Kedzierska
A University of Melbourne-led research team has cracked the riddle of how flu-killing immunity cells memorise distinct strains of influenza, which could lead to novel cellular memory-implant technologies resulting in a one-shot flu jab for life.
The extraordinary breakthrough in how ‘killer’ CD8+T cells (the body’s ‘army of hitmen’ tasked with taking out new viruses) retain memories of virus strains they encounter was published in the prestigious Nature Communications journal on May 13, 2015.
The Australia-Sino collaboration began during the first outbreak of the avian-derived H7N9 virus in China in 2013.
That contagion saw 99% of people infected hospitalised, with a 30% mortality rate.
‘Patient Zero’ was an elderly man who caught the virus from a chicken his wife asked him to buy at the local live bird market.
We have never seen anything like H7N9.
The virus was infecting more people rapidly and nobody had immunity. Thankfully, we managed to contain the virus but we knew that we had come face-to-face with a potential pandemic that could kill millions of people around the world if the virus became able to spread between humans.
These findings lead to the potential of moving from vaccines for specific influenza strains toward developing a protection, which is based on T-cells.
From the 30% mortality rate in China, we knew that the clock was ticking on the situation. Had the contagion spread broken out globally, we were talking about a history-altering event on the Spanish Flu scale.
As it turned out, boosting the T cell adaptive memory capacity was our entry.
Our extraordinary breakthrough could lead to the development of a vaccine component that can protect against all new influenza viruses, with the potential for future development of a one-off universal flu vaccine shot.
This work will also help clinicians to make early predictions of how well a patient’s immune system will respond to viruses so they can manage early interventions such as artificial ventilation more effectively, particularly in cases where the patient is at risk of dying
Published in Nature Communications, the research paper, titled, ‘Recovery from severe H7N9 disease,’ is associated with diverse response mechanisms dominated by CD8+T cells was led by the University of Melbourne and the Shanghai Public Health Clinical Centre and Fudan University in China, with scientists from St Jude Children’s Research Hospital, Memphis.
Co-author and Nobel Laureate Professor Peter Doherty from the University of Melbourne said, “After spending the past 40 years working on the virus-specific ‘killer’ T cells, this is the first study from our group that shows their role in protecting people against a novel human influenza A virus.”
Professor Xu, who co-led the study from Fudan University, said that this study would significantly enlighten T-cell based vaccine development and immune intervention during severe influenza infection in the future.
Professor Elizabeth Hartland, Head of the Department of Microbiology and Immunology at the University of Melbourne said that the international collaboration has brought together the immunological expertise in Melbourne and the clinical knowledge in Shanghai to produce a study of much higher impact than could be achieved individually.
“It exemplifies the approach we are taking at the Peter Doherty Institute for Infection and Immunity,” she said.
Dr Katherine Kedzierska is Associate Professor at the University of Melbourne.